How to Create a Psychiatric NP Intake Form for Psychiatric Nurse Practitioners (with Free Template)
This guide walks a Psychiatric Mental Health Nurse Practitioner (PMHNP) through the ten substantive steps of building an intake form that addresses APRN state scope of practice, collaborative practice agreement disclosure where required, DEA Schedule II prescribing, Ryan Haight Act and 2023 DEA telehealth rules for controlled substances, informed consent for psychotropic medication, suicide risk assessment, CMS E&M billing, drug-drug interaction documentation, refill protocol, and a tamper-evident audit trail. Each step is one paragraph of working guidance. Estimated time end-to-end: 45 minutes from blank document to signed PDF when using an AI form builder. Formfy is the AI form builder PMHNPs use to ship APRN scope-aware intake and controlled-substance disclosure in one workflow.
Before you start, gather six pieces of information: (1) the practitioner state APRN license, NPI, and DEA registration, (2) the state practice authority level (Full, Reduced, Restricted) per AANP categorization, (3) any collaborative practice agreement details and the collaborating physician contact, (4) the medications commonly prescribed (Schedule II to V), (5) the telehealth platform and the patient state of location, and (6) the standard psychotherapy add-on codes used. With those six inputs, the substantive drafting takes under 45 minutes.
Step 1: Define APRN scope of practice (state-specific)
Advanced Practice Registered Nurse scope of practice is state-specific. Each state Nurse Practice Act and Board of Nursing rules govern what an APRN, including a Psychiatric Mental Health Nurse Practitioner (PMHNP), can independently assess, diagnose, prescribe, and bill. The American Association of Nurse Practitioners categorizes states into Full Practice (independent practice authority), Reduced Practice (collaborative practice agreement required for at least one element), and Restricted Practice (delegation, supervision, or team management required) authority. The intake form must accurately disclose the practitioner state license, the level of practice authority, and the scope limits that apply. Misrepresenting scope is a state licensing-board violation. Verify the state-specific rule on each new state of practice before drafting.
Step 2: Address collaborative practice agreement (when required)
In Reduced and Restricted Practice states, a PMHNP typically must maintain a written collaborative practice agreement (sometimes called a supervisory agreement or collaborating physician agreement) with a physician licensed in the same state. The agreement defines the scope of practice, prescriptive authority, chart review cadence, and the procedures for escalation. Some states require the agreement to be filed with the Board of Nursing or the Board of Medicine. The intake form should disclose the existence of the collaborative practice agreement when required, name the collaborating physician, and acknowledge that certain treatment decisions may involve the collaborating physician. Patient acknowledgment of the model of care is best practice even in Full Practice states for transparency.
Step 3: Disclose DEA Schedule II prescribing
PMHNPs who prescribe controlled substances must hold an active DEA registration. Stimulant medications for ADHD (methylphenidate, amphetamine salts, lisdexamfetamine) are Schedule II controlled substances under the Controlled Substances Act (21 U.S.C. 801 et seq.). Benzodiazepines are Schedule IV. Buprenorphine for opioid use disorder is Schedule III. The intake form should disclose the practitioner DEA registration status, the schedules covered (which depends on state APRN prescriptive authority), and any program-level enrollments (Prescription Drug Monitoring Program access, state Stimulant Diversion Prevention rules where applicable). Some states require additional state controlled-substance certifications for APRN prescribers. The patient should acknowledge the Schedule II prescribing protocol in writing.
Step 4: Address Ryan Haight Act and 2023 telehealth rules
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (21 U.S.C. 829(e)) generally requires an in-person medical evaluation before a controlled substance can be prescribed via telehealth, with limited exceptions. During the COVID-19 public health emergency, the DEA waived the in-person requirement, allowing controlled-substance prescribing via telehealth. The DEA published a final rule in 2023 (followed by extensions and additional rulemaking through 2024 and 2025) governing the post-PHE framework. The current framework continues a temporary flexibility allowing certain controlled-substance prescribing via telehealth without an in-person visit, with requirements that vary by schedule and category. The intake form must disclose the practitioner telehealth controlled-substance protocol and reference the current DEA rule.
Step 5: Obtain informed consent for psychotropic medication
Informed consent for psychotropic medication is a standard of care across psychiatric prescribing. The American Psychiatric Association Practice Guideline framework and most state malpractice case law require disclosure of seven elements. First, the diagnosis and the rationale for medication. Second, the proposed medication name (generic and brand), dose range, and titration approach. Third, the expected benefits and the time course (most psychotropics take two to six weeks for full effect). Fourth, common side effects (over 5 percent incidence in clinical trials). Fifth, serious side effects, including FDA black-box warnings where applicable (suicidality in young adults on antidepressants, agranulocytosis on clozapine, tardive dyskinesia on antipsychotics). Sixth, alternatives including no treatment. Seventh, the discontinuation plan. The intake form should capture standardized acknowledgment of each element.
Step 6: Conduct suicide risk assessment and safety planning
Suicide risk assessment is required at every psychiatric intake. The Columbia Suicide Severity Rating Scale (C-SSRS) is the most widely used standardized tool and is referenced by the National Institute of Mental Health and the SAMHSA Suicide Prevention Resource Center. The intake form should incorporate C-SSRS or a comparable validated tool, capture historical suicide attempts and recent ideation, identify means access (firearm, medication stockpile, lethal means restriction conversation), and include a written safety plan template aligned with the Stanley-Brown Safety Planning Intervention. Disclose the practitioner duty to take reasonable safety measures including crisis-line referral, hospitalization referral, and involuntary commitment processes that vary by state. Document any 988 Suicide and Crisis Lifeline education provided.
Step 7: Address CMS E&M billing for psychiatric NP visits
PMHNPs typically bill Centers for Medicare and Medicaid Services (CMS) using Evaluation and Management (E&M) codes (99202 to 99205 for new patients, 99212 to 99215 for established patients) and psychotherapy add-on codes (90833, 90836, 90838) when psychotherapy is integrated into the medication management visit. The 2021 CMS E&M coding guidelines revision (effective January 2021) and the 2023 update revised documentation requirements, removing the History and Physical Exam scoring and basing level selection on Medical Decision Making or total time. The intake form should disclose the billing approach to the patient, capture insurance details, and document time spent (when time-based billing applies). Reference the 2023 CPT update if relevant. Some states mandate Good Faith Estimate disclosures under the No Surprises Act for self-pay.
Step 8: Document drug-drug interactions
Drug-drug interaction documentation is critical in psychiatric prescribing because patients commonly take medications from multiple specialties. The intake form should capture a complete medication reconciliation including prescription medications, over-the-counter medications, herbal supplements, cannabinoid use (medical cannabis is legal in many states; recreational cannabis is legal in a growing number of states), illicit drug use, and alcohol use. Specific interactions to screen for include MAOI-tyramine interactions, serotonin syndrome risk, QT-prolongation cumulative risk, CYP450 inducer or inhibitor effects on antidepressant and antipsychotic metabolism, and benzodiazepine-opioid concurrent use (FDA black-box warning). Connect the practitioner to the state Prescription Drug Monitoring Program. Document the interaction screen and the patient acknowledgment of disclosed risks.
Step 9: Set refill protocol and prescribing boundaries
Refill protocols prevent prescribing boundary violations. The intake form should disclose the practice refill policy: the standard refill cadence (commonly 30 days for Schedule II, up to 90 days for non-controlled), the appointment requirement to maintain prescriptions (typically every 30, 60, or 90 days based on stability), the early-refill policy (typically no early refills for Schedule II except documented loss with police report), the lost or stolen medication policy, the after-hours refill policy (urgent refills only, no Schedule II after hours), and the patient agreement to use a single pharmacy for controlled substances when state PDMP rules require pharmacy locking. Some practices use a Controlled Substance Agreement as a separate document; others integrate the protocol into the master intake.
Step 10: Sign and store securely (e-signature and audit trail)
Use an e-signature workflow that produces a tamper-evident audit trail with timestamp, IP address, and consent to electronic records. The federal ESIGN Act and UETA (adopted in 49 states) make e-signed intake and informed consent forms legally equivalent to wet-ink signatures for nearly all psychiatric uses. The DEA generally requires a separate Electronic Prescribing of Controlled Substances (EPCS) workflow with two-factor authentication for the actual controlled-substance prescription transmission, but the patient intake and informed consent can be e-signed under ESIGN. Store the signed packet (informed consent, controlled substance agreement, telehealth consent, suicide risk assessment, safety plan) in a HIPAA-compliant system that lets you retrieve files on 24-hour notice. Formfy and EHR-integrated platforms support tamper-evident audit trails.
Free template and downloadable PDF
Formfy ships a psychiatric NP intake template that maps one-to-one to the ten steps in this guide. The template is editable in the AI form builder: describe the state, the practice authority level, and the medication scope and the builder returns a delivery-ready intake packet with the APRN scope disclosure, collaborative practice agreement reference (when required), controlled-substance prescribing protocol, telehealth consent referencing the current DEA rule, psychotropic informed consent, C-SSRS-aligned suicide risk fields, and the e-signature block.
See also: /faq/psychiatric-nurse-practitioners-psychiatric-np-intake for the FAQ companion hub covering 17 of the most common psychiatric NP intake questions.
Related resources
Build a psychiatric NP intake packet in 45 seconds
Free 15-day Formfy trial. No credit card. Submission-based pricing.
Start your free trialLast verified: 2026-04-25. This page is informational; it is not legal or clinical advice. Practitioners should review state APRN scope rules, the current DEA telehealth controlled-substance rule, and CMS E&M coding guidance with counsel and qualified coders.